{"id":"W4392014388","doi":"10.1016/j.esmoop.2024.102254","title":"A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Principia Biopharma; Loxo Oncology; Chugai Pharmaceutical; EMD Serono; Genentech; Sierra Oncology; Astellas Pharma; Cancer Research UK; Seagen; MacroGenics; Ascentage Pharma; Menarini Group; F-star Therapeutics; Symphogen; Moderna; Pfizer; Innovent Biologics; Incyte; Mersana Therapeutics; Agios Pharmaceuticals; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; GlaxoSmithKline; Tizona Therapeutics; Helsinn; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Novartis Farmacéutica; Alexion Pharmaceuticals; Servier; Gilead Sciences; Sanofi; Helsinn Therapeutics; Amgen; Jounce Therapeutics; LAM Therapeutics; Celgene; Carrick Therapeutics; AstraZeneca; Onyx Pharmaceuticals; Eli Lilly and Company","keywords":"Monoclonal antibody; Antibody; Solid tumor; Dosing; Cancer research; Medicine; Monoclonal; Internal medicine; Immunology; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003220506,0.0001766774,0.0003894576,0.0001419062,0.00007324183,0.00004889165,0.0003433824,0.00004686601,0.0002239658],"category_scores_gemma":[0.00002157887,0.0001102919,0.00005768428,0.0006569244,0.00008707761,0.0001924904,0.0001709699,0.0002544991,0.000004912733],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000203169,"about_ca_system_score_gemma":0.0001474558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002458775,"about_ca_topic_score_gemma":0.005828758,"domain_scores_codex":[0.9985534,0.00006889529,0.0004507609,0.0003565966,0.0003345704,0.0002357553],"domain_scores_gemma":[0.9992958,0.00003613673,0.00009624658,0.0004846292,0.00004309025,0.00004408212],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03166512,0.01706408,0.8924798,0.0005101821,0.0005062176,0.0003781977,0.02244433,0.00008283034,0.001861771,0.00006564824,0.002290523,0.0306513],"study_design_scores_gemma":[0.04314611,0.006994846,0.9370839,0.002963057,0.00006953928,0.000005418034,0.001843052,0.00006775911,0.002953259,0.00003651063,0.004586334,0.0002501957],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950339,0.0001397871,7.105732e-7,0.000464168,0.0002002409,0.002822296,0.00001533505,0.00001949609,0.001304019],"genre_scores_gemma":[0.9990754,0.00001140774,0.00003076189,0.0001508945,0.00003141011,0.0001457698,0.00001713954,0.00003337222,0.0005039042],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04460412,"threshold_uncertainty_score":0.4497575,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01321478690260793,"score_gpt":0.3212640118319691,"score_spread":0.3080492249293612,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}